Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
January 16, 2024 3:59 AM 2 min read

Anthony Fauci's Ex-Boss Now Admits COVID-19 Lab Leak Theory Is Credible And 'Not A Conspiracy'

by Benzinga Neuro Benzinga Staff Writer
Follow

Former head of the National Institutes of Health (NIH) Francis Collins acknowledged the credibility of the COVID-19 lab leak theory, a concept he previously labeled as a “distraction.”

What Happened: Collins, who was once the boss of Dr. Anthony Fauci, disclosed this during a private, seven-hour session with the House Select Committee on Coronavirus Pandemic, Fox News reported on Monday.

Rep. Brad Wenstrup (R-Ohio), the subcommittee’s chairman, revealed key insights from the interview with Collins, asserting that Collins acted as Fauci’s “boss.”

Collins confessed that the lab leak theory was indeed credible. This admission is in line with Fauci’s own acknowledgment in an earlier meeting with the subcommittee that the lab leak theory was not a conspiracy.

“Dr. Collins agreed with Dr. Fauci's concession that the COVID-19 lab leak hypothesis is not a conspiracy,” Wenstrup wrote after Collins’ interview.

Collins also vaguely defined gain-of-function research, possibly to conceal the NIH’s role in funding Wuhan-based research. He contradicted Fauci’s previous statements and raised questions about the U.S. government’s role in suppressing and discrediting the lab leak hypothesis.

See Also: Cannabis And Covid: Preventive And Long-Term Therapeutic Approach Revealed In New Study

Collins further agreed with Fauci’s assessment that the six-feet social distancing rule was likely not based on scientific data.

Why It Matters: The lab leak theory has been a contentious issue since the pandemic’s early days. In February, U.S. intelligence leaned towards the lab leak theory. However, China rebuked the U.S. for rehashing the theory in March, calling it a politicization of the tracing process.

In September, allegations arose that Fauci may have secretly influenced the CIA investigation into the virus’s origins. SSCP chairman Wenstrup alleged that Fauci pushed a particular narrative in an attempt to falsify the lab leak theory.

Fauci was formerly the top U.S. infectious disease official who became the face of America’s COVID-19 pandemic response.

Read Next: Huge Study Reveals Cannabis Provides Similar Pain Relief Benefits As Opioids Without Negative Consequence

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
NewsHealth CarePoliticsTop StoriesAnthony FauciCovid-19Kaustubh Bagalkote
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter

Engineered by Benzinga Neuro, Edited by Kaustubh Bagalkote


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Comments
Loading...